Fertility sparing approach to vaginal clear cell adenocarcinoma: a case report

Introduction: Four to nine percent of vaginal adenocarcinomas are clear cell adenocarcinomas. The most frequently used therapeutic approach for Stage I vaginal clear cell carcinoma is partial or total vaginectomy combined with radical hysterectomy and pelvic lymphadenectomy. Radical trachelectomy has also become a preferred treatment modality in recent years especially for patients who wish to retain fertility. Case: A 22-year-old nulligravid women was presented to hospital with the complaint of infertility. Gynecological examination revealed two eccentric masses extending from proximal part of the anterior vaginal wall with a diameter of 0.5 cm and 0.5 cm. Histopathological evaluation resulted as clear cell adenocarcinoma. Positron emission tomography/computed tomography (PET/CT) and abdominopelvic magnetic resonance imaging (MRI) revealed no pathologic lymph node involvement and metastatic lesion. Patient was diagnosed as vaginal clear cell adenocarcinoma, FIGO Stage 1, T1N0M0. The patient was informed about each treatment option and patient was scheduled for radical abdominal trachelectomy and lymph node dissection. Frozen section procedure of bilateral pelvic lymph nodes were consistent with the absence of metastasis. Then a radical abdominal trachelectomy was performed. Definitive pathology revealed clear cell adenocarcinoma of the vagina, no pelvic lymph nodes involvement, and negative surgical margins. Adjuvant treatment was not needed. Patient has been followed up every three months by vaginal and cervical smear for 30 months. Postoperative 30th month control revealed no pathologic findings and patient had been menstruating regulary. Conclusion: Strict treatment guidelines however, cannot be formulated and optimal therapeutic approaches must be individualized; radical trachelectomy is a potential fertility sparing procedure described for early stage clear cell carcinoma.

Vagina; Clear cell adenocarcinoma; Fertility preservation; Trachelectomy.

[1] Cardenes H., Roth L., McGuire W., Look K.: “Vagina”. In: HoskinsW., Perz C., Young R., Barakat R., Markman M., Randall M., (eds). Principles and Practise of Gynecologic Oncology, 4th edn. Philadelphia: Lippincott Williams&Wilkins, 2005, 707.

[2] Herbst A.L., Ulfelder H., Poskanzer D.C.: “Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women”. N. Engl. J. Med., 1971, 284, 878.

[3] Herbst A.L., Anderson D.: “Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diathylstilbestrol”. Semin. Surg. Oncol., 1990, 6, 343.

[4] Frank S.J., Deavers M.T., Jhingran A., Bodurka D.C., Eifel P.J.: “Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure”. Gynecol. Oncol., 2007, 105, 470.

[5] Herbst A.L., Kurman R.J., Scully R.E., Poskanzer D.C.: “Clear cell adenocarcinoma of the genital tract in young females: registry report”. N. Engl. J. Med., 1972, 287, 1259.

[6] Herbst A.L., Anderson D.: “Clinical correlations and management of vaginal and cervical clear cell adenocarcinoma”. In: Herbst A.L., Bern H.A., (eds). Developmental effects of diethylstilbestrol (DES) in pregnancy. New York: Thieme-Stratton, 1981, 71.

[7] Herbst A.L., Norusis M.J., Rosenow P.J., Welch W.R.: “Scully RE. An analysis of 346 cases of clear cell adenocarcinoma of the vagina and cervix with emphasis on recurrence and survival”. Gynecol. Oncol., 1979, 7, 111.

[8] Robboy S.J., Herbst A.L., Scully R.E.: “Clear cell adenocarcinoma of the vagina and cervix in young females: Analysis of 37 tumors that persisted or recurred after primary therapy”. Cancer, 1974, 34, 606.

[9] Davis K., Stanhope C., Garton G., Atkinson E., O’Brien P.: “Invasive vaginal carcinoma: analysis of early-stage disease”. Gynecol. Oncol., 1991, 42, 131.

[10] Stock R.G., Chen A., Seski J.: “A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities”. Gynecol. Oncol., 1994, 56, 45.

[11] Senekjian E., Frey K., Anderson D., Herbst A.: “Local therapy in Stage I Clear cell Adenocarcinoma of the vagina”. Cancer, 1987, 60, 1319.

[12] Creasman W., Phillips J., Menck H.: “The National Cancer Data Base report on cancer of the vagina”. Cancer, 1998, 83, 1033.

[13] The University of Chicago: “Registry for research on hormonal transplacental carcinogenesis”. Available at: http://obg.bsd.uchicago. edu/registry.html